205 related articles for article (PubMed ID: 31873944)
21. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
[TBL] [Abstract][Full Text] [Related]
22. Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Vidisheva AP; Wang J; Spektor TM; Bitran JD; Lutzky J; Tabbara IA; Ye JZ; Ailawadhi S; Stampleman LV; Steis RG; Moezi MM; Swift RA; Maluso TM; Udd KA; Eshaghian S; Nassir Y; Berenson JR
Support Care Cancer; 2017 Oct; 25(10):3217-3224. PubMed ID: 28455546
[TBL] [Abstract][Full Text] [Related]
23. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
25. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Velasco R; Petit J; Clapés V; Verdú E; Navarro X; Bruna J
J Peripher Nerv Syst; 2010 Mar; 15(1):17-25. PubMed ID: 20433602
[TBL] [Abstract][Full Text] [Related]
26. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Brossart P; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2016 Dec; 101(12):e485-e487. PubMed ID: 27540135
[No Abstract] [Full Text] [Related]
27. Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy.
Lee SE; Choi K; Han S; Lee J; Hong T; Park GJ; Yim DS; Min CK
Anticancer Drugs; 2017 Jul; 28(6):660-668. PubMed ID: 28430745
[TBL] [Abstract][Full Text] [Related]
28. Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy.
Yamamoto S; Egashira N
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477371
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
.
Hu B; Zhou Q; Wu T; Zhuang L; Yi L; Cao J; Yang X; Wang J
Int J Clin Pharmacol Ther; 2017 Apr; 55(4):329-338. PubMed ID: 28079515
[TBL] [Abstract][Full Text] [Related]
30. Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma.
Moore DC; Ringley JT; Nix D; Muslimani A
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):168-173. PubMed ID: 32029398
[TBL] [Abstract][Full Text] [Related]
31. Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.
Castro TB; Hallack Neto AE; Atalla A; Ribeiro LC
Braz J Med Biol Res; 2016; 49(6):e5128. PubMed ID: 27254660
[TBL] [Abstract][Full Text] [Related]
32. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.
Magrangeas F; Kuiper R; Avet-Loiseau H; Gouraud W; Guérin-Charbonnel C; Ferrer L; Aussem A; Elghazel H; Suhard J; Sakissian H; Attal M; C Munshi N; Sonneveld P; Dumontet C; Moreau P; van Duin M; Campion L; Minvielle S
Clin Cancer Res; 2016 Sep; 22(17):4350-4355. PubMed ID: 27060151
[TBL] [Abstract][Full Text] [Related]
33. Foot drop in patients treated with bortezomib - a case series and review of the literature.
Vaxman I; Mauerman ML; Gatt ML; Berger T; Gertz MA
Leuk Lymphoma; 2022 Mar; 63(3):722-728. PubMed ID: 34702127
[TBL] [Abstract][Full Text] [Related]
34. Mechanistic Involvement of Inflammation in Bortezomib-induced Peripheral Neuropathy.
Goel L; Gupta P; Pahuja M
Comb Chem High Throughput Screen; 2022; 25(10):1595-1600. PubMed ID: 35611787
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.
Aguiar PM; de Mendonça Lima T; Colleoni GWB; Storpirtis S
Crit Rev Oncol Hematol; 2017 May; 113():195-212. PubMed ID: 28427509
[TBL] [Abstract][Full Text] [Related]
36. [Incidence and Risk of Peripheral Neuropathy Caused by Intravenous and Subcutaneous Injection of Bortezomib].
Liu ZQ; Xia HL; Li CJ; Xia L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1654-1663. PubMed ID: 31607328
[TBL] [Abstract][Full Text] [Related]
37. Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics.
Kul AN; Ipek Y
J Oncol Pharm Pract; 2023 Oct; 29(7):1652-1660. PubMed ID: 36237141
[TBL] [Abstract][Full Text] [Related]
38. Therapy-related peripheral neuropathy in multiple myeloma patients.
Morawska M; Grzasko N; Kostyra M; Wojciechowicz J; Hus M
Hematol Oncol; 2015 Dec; 33(4):113-9. PubMed ID: 25399783
[TBL] [Abstract][Full Text] [Related]
39. Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study.
Maschio M; Maialetti A; Marchesi F; Gumenyuk S; Pisani F; Papa E; Galiè E; Koudriavtseva T; Graziano G; Giannarelli D; Mengarelli A
Integr Cancer Ther; 2022; 21():15347354221114142. PubMed ID: 35866451
[TBL] [Abstract][Full Text] [Related]
40. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
